Exemestane

This page contains recent news articles, when available, and an overview of Exemestane but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Exemestane (when available)

Pharmacology and use:
aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (ArimidexÆ), letrozole (FemaraÆ) and exemestane (AromasinÆ). For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Mechanism Of Action:
Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.

News Articles on Exemestane

Confederação de atletismo confirma doping de mais dois brasileiros  -  ‎Oct 19, 2009‎
Os dois atletas foram pegos pelo uso das substâncias proibidas Exemestane (Metabólitos) e Boldenona (Metabólitos). Eles foram comunicados em 16 de setembro ... Zero Hora

Aromasin nel trattamento del tumore al seno a insorgenza precoce  -  ‎Nov 4, 2009‎
I dati clinici hanno mostrato i benefici sulla sopravvivenza passando a Exemestane dopo 2-3 anni.di terapia con Tamoxifene. Su un totale di 4.742 pazienti, ... XagenaSalute

Doping de Daiane se soma a casos ocorridos também no atletismo em 2009  -  ‎Oct 30, 2009‎
...encontrada em produtos veterinários e comumente usada em cavalos, e exemestane, utilizada para atenuar os efeitos colaterais da primeira, ... O Globo

Letrozolo nel cancro mammario  -  ‎Oct 23, 2009‎
Tuttavia in questi ultimi anni si sono imposti gli inibitori dell'aromatasi (anastrozolo, letrozolo, exemestane). I risultati dello studio ATAC [1] sembrano ... Pillole.org

Posted 10 hours ago  -  13 Jul 2009
...women at increased risk of developing breast cancer for a clinical trial to evaluate the role of the drug Exemestane in the prevention of breast cancer. Sudbury Star

RCP Breast Cancer Study  -  ‎Jul 8, 2009‎
...women at increased risk of developing breast cancer for a clinical trial to evaluate the role of the drug Exemestane in the prevention of breast cancer. NorthernLife.ca

Breast Cancer Research Study  -  ‎Apr 17, 2009‎
...women at increased risk of developing breast cancer for a clinical trial to evaluate the role of the drug Exemestane in the prevention of breast cancer. NorthernLife.ca

Breast Cancer: Preoperative Chemotherapy  -  ‎Mar 31, 2009‎
Abstract Phase III randomized study of neoadjuvant therapy comprising exemestane versus letrozole versus anastrozole in postmenopausal women with estrogen Medscape

Ostéoporose, traitements hormonaux et prévention  -  ‎Apr 15, 2009‎
Chez la femme ménopausée Chez la femme ménopausée, on utilise seuls les antiaromatases, soit le letrozole ou anastrozole, ou encore l’exemestane Vie Femme

Π�?ώιμος κα�?κίνος του μαστο�?  -  ‎Apr 8, 2009‎
Exemestane, Adjuvant, Multicenter), η οποία π�?αγματοποιήθηκε σε εννέα χώ�?ες, μεταξ�? των οποίων και η Ελλάδα, με τη συμμετοχή 9.775 ασθενών. My World

�?��?�乳癌婦比�?美年輕10歲  -  ‎Feb 24, 2009‎
...在治療方�?�，據統計，�?��?��?�經後的乳癌女性患者中，近八�?�?�?�爾蒙治療有效，而�?�項臨床�?果顯示，Exemestane治療效果�?錯。包括美國�?日本�?韓國等國家，都已將芳香環聯合新聞網

Κα�?κίνος μαστο�?: Εμφανίζεται συχνότε�?α, αντιμετωπίζεται ...  -  04 Feb 2009
...‘ΤΕΑΜ’ (Tamoxifen, Exemestane, Adjuvant, Multicenter), π�?αγματοποιήθηκε σε εννέα χώ�?ες, μεταξ�? των οποίων και η Ελλάδα, με τη συμμετοχή 9.775 ασθενών. Ιατ�?οnet,

Growth Factor Associated With More Deadly Breast Tumors  -  Feb 3, 2009
Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin® or an aromatase inhibitor RedOrbit,

Advances in the Treatment of Early-stage Breast Cancer: A Report ...  -  Feb 3, 2009
Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive Cancer Consultants,

What's the evidence for aromatase inhibitors for early breast cancer?  -  Jan 21, 2009
In one study of 4742 women (a randomised controlled trial), switching to exemestane after taking tamoxifen for two to three years reduced the chance of guardian.co.uk,

New Therapies Vie for Role in Breast Cancer  -  Jan 23, 2009
The IGF-R1 inhibitor CP-751871 is being evaluated with exemestane (Aromasin) in an ongoing randomized clinical trial involving patients with ER-positive MedPage Today,

SABCS: Exemestane Modestly Improves on Tamoxifen for Initial ...  -  Dec 15, 2008
15 -- For postmenopausal women with hormone-sensitive early stage breast cancer, exemestane (Aromasin) may be a modestly better initial adjuvant therapy MedPage Today,

Aromasin (exemestane) Shows Some Advantages Over Tamoxifen As ...  -  Dec 17, 2008
Interim findings of the TEAM (Tamoxifen Exemestane Adjuvant Multicenter) trial reported on 11th December at the 2008 San Antonio Breast Cancer Symposium Medical News Today,

Osteoporosis Drug Seems to Shrink Breast Tumors  -  Dec 11, 2008
..."Exemestane is very effective at preventing recurrences," said Dr. Stephen Jones, medical director of US Oncology Research in Houston. Washington Post,

Femara®, Aromasin® Superior to Tamoxifen in Early Breast Cancer  -  Dec 19, 2008
Results from two separate studies have indicated that the aromatase agents Femara® (letrozole) and Aromasin® (exemestane) improve outcomes compared with Cancer Consultants,

Pfizer Announces Results from Trial of AROMASIN in Postmenopausal ...  -  Dec 11, 2008
TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN® (exemestane tablets) vs. tamoxifen. In 2004, based on results of WELT ONLINE,

Treatment Updates  -  Dec 23, 2008
The TEAM trial asked whether five years of Aromasin (exemestane) or tamoxifen works better as single-agent therapy after surgery. The first analysis of this Curetoday.com (press release),

XplosiveStocks.com: Pfizer (NYSE:PFE) Hot Stock on the Move!  -  Dec 15, 2008
TEAM was originally designed in 2001 as a comparison of 5 years of upfront AROMASIN(R) (exemestane tablets) vs. tamoxifen. In 2004, based on results of Trading Markets (press release),

Aromatase Inhibitors Demonstrate Long-Term Benefit Versus ...  -  Dec 13, 2008
15.3% experienced recurrence on aromatase inhibitors (anastrozole, exemestane, and letrozole) compared with 19.2% of those on tamoxifen (P < .00001). DG News

화�?��? 유방암 치료제 '아로마신' 타목시펜보다 효과 떨어져  -  Dec 11, 2008
...［메디컬투�?��?� 곽�?��?� 기�?］ 화�?��?�?� 유방암 치료제 '아로마신(Aromasin : exemestane)'�?� 호르몬�?수성조기유방암�?� 발병한 �??경 여성�?서 수명�?� 늘리는�?� 있어서 마�?��?��?�리,

Exemestano reduce en un 15% el riesgo de recaída en el tratamiento ...  -  Dec 17, 2008
Estas son dos de las primeras conclusiones del análisis inicial del estudio TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter, por sus siglas en inglés) un acceso.com (Comunicado de prensa),

Causes Of Bone Loss In Breast Cancer Survivors Include Cancer ...  -  Nov 20, 2008
Aromatase inhibitors include letrozole (trade name, Femara), anastrazole (Arimidex) and exemestane (Aromasin). Researchers reviewed charts of 238 Science Daily (press release)

Research boosts survival  -  Nov 1, 2008
There are three drugs in this class: anastrozole, letrozole and exemestane. They are used only in post menopausal women. Finally, we have fulvestrant, Malaysia Star,

�?약청, 주간 임�?시험계�? 승�?� 현황  -  Nov 13, 2008
...병용 유무 시 FaslodexTM를 Exemestane과 비�? �?�가하기 위하여 한국아스트�?�제네카가 삼성서울병�? 등�? �?�뢰하여 실시하는 �?�약품 임�?시험계�? 등 7건과, 뉴스와�?�어,

�?약청, 한미약품 ‘암로디핀’ 등 1  -  Nov 14, 2008
...(ArimidexTM) 병용 유무 시 Fulvestrant (FaslodexTM)를 Exemestane과 비�?한 부분-눈가림, 무작위 배정, 3�? 임�?시험�?� 삼성서울병�?등�?서 실시할 예정�?�다. 헬스코리아뉴스,

한국아스트�?�제네카， 진행성 유방암 치료제 ‘파슬로�?�스’  -  Oct 29, 2008
EFECT(Evaluation of Faslodex vs Exemestane Clinical Trial) 연구�?서 �?�전�? 호르몬 치료를 받�?� 후 질병�?� 진행�?� 여성�?� 파슬로�?�스로 치료한 결과 35.1%�?� 환�? 쿠키뉴스,

UK women with breast cancer at risk of missing out on optimal care  -  Oct 6, 2008
Exemestane (Aromasin) is indicated for the adjuvant treatment of postmenopausal women with oestrogen-receptor positive invasive early breast cancer, PharmiWeb.com (press release),

Breast cancer awareness  -  Oct 20, 2008
...women with early or advanced breast cancer that is hormone-receptor positive: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). GoErie.com,

Battling Breast Cancer  -  Oct 17, 2008
...women with early or advanced breast cancer that is hormone-receptor positive: letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin). Providence Journal,

New Concepts and Therapeutic Approaches for Early-Stage Breast Cancer  -  Oct 17, 2008
...which will compare exemestane with placebo. All of these drugs appear to reduce the incidence of estrogen receptor (ER)-positive breast cancers only. Medscape (subscription)

Acupuncture May Help With Side Effects of Hormone Therapy, Study Finds  -  Oct 11, 2008
And drugs called aromatase inhibitors – letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin) -- have been approved to treat both ACS News Center,

Delayed Adjuvant Chemotherapy in Breast Cancer  -  Sep 30, 2008
A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with Medscape (subscription)

Geen compensatie voor kankerpatiënten met hormoongevoelige medicatie  -  Oct 6, 2008
...(Tamoxifen) letrozole (Femara), exemestane (Aromasin) en anastrozole (Arimidex) ook op de lijst van medicijnen zou staan. Dit blijkt niet het geval. Nieuwsbank (abonnement),

Growth Factor Predicts Poor Outcome In Breast Cancer  -  Aug 29, 2008
Currently, the Breast Center is studying the effects of an IGF receptor antibody combined with a drug called exemestane (Aromasin® or an aromatase inhibitor Science Daily (press release)

My quest for the holy grail of breast cancer treatment  -  Aug 22, 2008
...cats are getting just a little tired of hearing me try to pronounce things like "armamentarium" and drugs such as letrozole, anastrozole and exemestane. The Kingston Whig-Standard,

Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to ...  -  Sep 8, 2008
Data on the following compounds will also be presented at ESMO: Aromasin(®) (exemestane), Campto(®) (irinotecan HCl), axitinib and tremelimumab. WELT ONLINE,

Drug Re-Sensitizes Breast Tumors to Treatment  -  Sep 5, 2008
2008 ASCO Breast Cancer Symposium in Washington, DC Isaacs is part of the speaker's bureau for Pfizer Inc., which makes the aromatase inhibitor Exemestane. Washington Post,

�?��?린 닮�?� 성장�?��? '유방암' 예후 결정  -  Sep 2, 2008
...연구팀�?� 현재 유방암�? 대해 '아로마신(Aromasin:exemestane)'�?��?�는 약물과 IGF 수용체 항체를 병행 치료�?� 효과를 연구중�?�다. 메디컬투�?��?� 조고�?� 기�?. 마�?��?��?�리,

Early Phase Breast Cancer Study At GUMC Suggests New Approach Can ...  -  Sep 8, 2008
Isaacs is part of a speaker's bureau for Pfizer the maker of Exemestane, an aromatase inhibitor. Georgetown University Medical Center is an internationally Medical News Today (press release),

Zoledronic Acid Significantly Reduced Relapse in Early Breast Cancer  -  Jun 17, 2008
...exemestane (Aromasin, Pfizer), and the BIG 3-02 study, which is comparing an LHRH agonist plus tamoxifen with an LHRH agonist and exemestane. Abkhazia,

New treatment strategies for women with early-stage breast cancer ...  -  02 Jun 2008
But have they been seduced by switching trials such as the IES (Intergroup Exemestane Study)? In the IES, 4724 postmenopausal women with EBC who were ecancermedicalscience,

Zolendronic Acid Significantly Reduced Relapse in Early Breast Cancer  -  02 Jun 2008
...exemestane (Aromasin, Pfizer), and the BIG 3-02 study, which is comparing an LHRH agonist plus tamoxifen with an LHRH agonist and exemestane. Medscape (subscription)

Early Breast Cancer: A Patient's Story  -  May 16, 2008
Now she's sharing her story of why she switched to AROMASIN ® (exemestane tablets). Select a topic below to hear Valerie's response. WebMD

New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer ...  -  May 16, 2008
Data on the following compounds will also be presented at ASCO 2008: Aromasin ® (exemestane), Camptosar ® (irinotecan HCl), CP-868596, PF-3512676, Earthtimes (press release),

Deciding on breast cancer treatment: Tamoxifen versus aromatase ...  -  May 13, 2008
The FDA has approved three aromatase inhibitors: anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Tamoxifen is effective in both pre- Gather.com,

Specific Gene Mutations May Affect Response to Tamoxifen in Breast ...  -  May 12, 2008
Newer agents, however, referred to as aromatase agents (Femara® [letrozole], Arimidex® [anastrozole], and Aromasin® [exemestane]), are now commonly used for Cancer Consultants,

Study looks for women to take free pill  -  Apr 18, 2008
Not even the pharmacy will know if the pill it dispenses to volunteers is Exemestane or a placebo that has no effect at all. Almost 3000 women from Canada, NorthernLife.ca,

Celecoxib Doesn't Improve Breast Cancer Therapy Response  -  Apr 2, 2008
NEW YORK APR 01, 2008 (Reuters Health) - Despite promising experimental findings, addition of celecoxib to exemestane therapy in postmenopausal women with Cancerpage.com,

EBBC: Aromatase Inhibitors Do Not Increase Cardiovascular Risks  -  Apr 18, 2008
An analysis of several trials comparing anastrozole (Arimidex), letrozole (Femara), and exemestane (Aromasin) with tamoxifen or placebo found no added risk MedPage Today,

New research shows no link between aromatase inhibitors and ...  -  Apr 17, 2008
AIs, such as letrozole, anastrozole and exemestane, work by causing severe oestrogen deprivation and, increasingly, they are being prescribed for women EurekAlert (press release),

NSAIDs and Breast Cancer: A Possible Prevention and Treatment Strategy  -  Mar 25, 2008
Canney PA, Machin MA, Curto J. A feasibility study of the efficacy and tolerability of the combination of exemestane with the cyclooxygenase inhibitor in Medscape (subscription)

Novartis’ Femara Significantly Reduces Breast Cancer Recurrence  -  11 Mar 2008
Dr’ Goss said his results would likely apply to all aromatase inhibitors: Pfizer Inc’s exemestane, sold under the brand Aromasin and AstraZeneca Plc’s eFluxMedia

Femara cuts cancer recurrence even if started late  -  11 Mar 2008
Pfizer Inc makes an aromatase inhibitor called exemestane, which it sells under the brand Aromasin, and AstraZeneca Plc makes anastrozole, sold under the Scientific American

Update: A 62-Year-Old Woman With a New Diagnosis of Breast Cancer  -  Mar 4, 2008
As planned, I switched to taking exemestane. But while taking it, I was feeling like I was a hundred years old. When I got up in the morning and opened my Journal of American Medical Association (subscription),

Experts Available to Discuss Study Showing Link Between High ...  -  Mar 7, 2008
His research and publications include: Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), PharmaLive.com (press release),

Can aspirin reduce breast cancer risk?  -  Mar 7, 2008
The authors also discuss several studies that looked at the use of the NSAID celecoxib in combination with exemestane (a hormone therapy) in women with NHS Choices,

Breast Cancer Incidence Rising In Asian Women At Younger Age ...  -  Feb 18, 2008
Her cancer was HER2/neu and oestrogen receptor-positive and was treated with the aromatase inhibitor exemestane. However, she was subsequently found to have Medical News Today,

Brand Names/Synonyms:
Exemestane is also known by the following brand names and/or synonyms:
Aromasin; EXEMESTANE; Exemestance; Exemestane; Exemestane [Inn]; Exemestane [Usan:Inn:Ban]; Exemestano [Inn-Spanish]; Exemestanum [Inn-Latin]

Drug Category:
Exemestane is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BG06

Dosage Forms:
tablets

Absorption:
42%

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.